China Performs First Cancer Patient Treatments in the Xiamen Humanity Hospital Using Novel Accelerator-based Radiation Oncology Therapy (BNCT)
27 Feb 2023
Radiation TherapyClinical Study
XIAMEN, China--(BUSINESS WIRE)--Neuboron Medical Group (NMG), a leading global Accelerator-based Boron Neutron Capture Therapy (AB-BNCT) total solution provider today announced that the first AB-BNCT cancer research center in China, Xiamen Humanity Hospital (XHH) BNCT Center has successfully performed 14 irradiations on 12 patients for its first Investigator Initiated Trial (IIT) aimed to evaluate the safety and efficacy of BNCT in the treatment of advanced refractory malignant tumors. With this milestone, China has become the second country to master and utilize accelerator BNCT technology.
The clinical protocol relied on a full suite of NeuPex AB-BNCT device system and NeuMANTA® Treatment Planning system, boron-containing drug BPA and PET imaging drug F-BPA supplied from Neuboron. NeuPex is a highly integrated and sophisticated medical system that consists of a Beam Shaping Assembly, Accelerator, Patient Positioning System, Dose Monitoring System, QC/QA System, Medical User Control system and Interlocks, etc. Benefiting from Neuboron’s unique beam control technology, the NeuPex system under the proton condition of 18.4 kW/2.3 MeV/8 mA (the highest efficiency of AB-BNCT system in clinical use worldwide) has already met the clinical criteria. The accelerator for the NeuPex system is manufactured by Neuboron’s partner TAE Life Sciences.
This clinical research was launched on Oct. 9, 2022, after being validated by a large number of animal preclinical studies and approved by Xiamen Humanity Hospital’s Institutional Review Board (IRB). These twelve patients were diagnosed with recurrent head and neck, high-grade glioma, and melanoma cancers with traditional cancer therapies exhausted.
After a 3-month follow-up, the first 4 patients showed satisfactory safety and superior tumor control performance. All of them showed tumor regression. The 12 patients will have remained follow-up observation accordingly. The clinical study preliminarily not only verifies the safety of the combined treatment of neutron radiation and BPA drug, but also demonstrated good clinical treatment value.
“The completion of our first-in-human clinical study at this stage demonstrates great efficacy and safety using novel in-hospital accelerator-based BNCT,” said Prof Yuan-Hao Liu, Ph.D., CEO and CSO of Neuboron Medical Group. “This milestone marks a great potential to treat recurrent, advanced, and refractory cancer.” “We are very excited to have witnessed this binary radiotherapy expanding our patient’s lives and will continue to work tirelessly on our end to bring our one-stop BNCT total solution to the global market as quickly as possible,” emphasized Prof. Dr. Liu.
About BNCT
Boron Neutron Capture Therapy (BNCT) is a targeted radiation oncology therapy in that neutron beams destroy only boron compound-bearing tumors without destroying neighboring healthy tissue. BNCT has significant advantages of delivering highly effective and very cell-centralized radiation therapy in treating patients with recurrent, invasive, and local-regional metastases refractory tumors with a relatively low impact on the patient’s quality of life. To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide.
About Neuboron Medical Group
Neuboron Medical Group (NMG) was founded in 2014 in Nanjing and then expanded to Xiamen in China. It is the 1st and only company in China focused on providing Boron Neutron Capture Therapy (BNCT) total solution to hospital users, including hardware, software, and boron drugs. Neuboron is a research and development-oriented enterprise that has built integrative and comprehensive know-how and capability over the whole BNCT technology. Neuboron has installed China’s first hospital-based compact AB-BNCT medical system (aka. NeuPex) since August 2021 and has undergone the first-in-human study at Xiamen Humanity Hospital (XHH) BNCT Center in 2022.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.